NCT02668770View on ClinicalTrials.gov

Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 11, 2016

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced CancersMelanoma
Interventions
DRUG

MGN1703

"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.~Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."

DRUG

Ipilimumab

Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Mologen AG
All Listed Sponsors
collaborator

Mologen AG

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT02668770 - Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | Biotech Hunter | Biotech Hunter